Zoetis Inc (ZTS)
174.25
+3.88
(+2.28%)
USD |
NYSE |
Nov 07, 16:00
174.99
+0.74
(+0.42%)
Pre-Market: 08:39
Zoetis Revenue (TTM): 9.152B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 9.152B |
| June 30, 2024 | 8.915B |
| March 31, 2024 | 8.734B |
| December 31, 2023 | 8.544B |
| September 30, 2023 | 8.371B |
| June 30, 2023 | 8.222B |
| March 31, 2023 | 8.094B |
| December 31, 2022 | 8.08B |
| September 30, 2022 | 8.007B |
| June 30, 2022 | 7.995B |
| March 31, 2022 | 7.891B |
| December 31, 2021 | 7.776B |
| September 30, 2021 | 7.616B |
| June 30, 2021 | 7.412B |
| March 31, 2021 | 7.012B |
| December 31, 2020 | 6.675B |
| September 30, 2020 | 6.542B |
| June 30, 2020 | 6.34B |
| March 31, 2020 | 6.339B |
| December 31, 2019 | 6.26B |
| September 30, 2019 | 6.15B |
| June 30, 2019 | 6.046B |
| March 31, 2019 | 5.914B |
| December 31, 2018 | 5.825B |
| September 30, 2018 | 5.721B |
| Date | Value |
|---|---|
| June 30, 2018 | 5.588B |
| March 31, 2018 | 5.442B |
| December 31, 2017 | 5.307B |
| September 30, 2017 | 5.124B |
| June 30, 2017 | 5.018B |
| March 31, 2017 | 4.957B |
| December 31, 2016 | 4.888B |
| September 30, 2016 | 4.885B |
| June 30, 2016 | 4.858B |
| March 31, 2016 | 4.825B |
| December 31, 2015 | 4.765B |
| September 30, 2015 | 4.811B |
| June 30, 2015 | 4.807B |
| March 31, 2015 | 4.79B |
| December 31, 2014 | 4.785B |
| September 30, 2014 | 4.719B |
| June 30, 2014 | 4.612B |
| March 31, 2014 | 4.568B |
| December 31, 2013 | 4.561B |
| September 30, 2013 | 4.483B |
| June 30, 2013 | 4.399B |
| March 31, 2013 | 4.379B |
| December 31, 2012 | 4.336B |
| September 30, 2012 | 4.287B |
| June 30, 2012 | 4.317B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
6.26B
Minimum
Dec 2019
9.152B
Maximum
Sep 2024
7.699B
Average
7.943B
Median
Revenue (TTM) Benchmarks
| Pfizer Inc | 59.37B |
| Alnylam Pharmaceuticals Inc | 2.095B |
| Biomarin Pharmaceutical Inc | 2.753B |
| Corcept Therapeutics Inc | 628.56M |
| Ionis Pharmaceuticals Inc | 803.07M |